Variable antiviral activity of islatravir against M184I/V mutant HIV-1 selected during antiretroviral therapy
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkad390 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Paula C Aulicino und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cellular Biology and Retroviruses, Unit of Virology and Molecular Epidemiology, Hospital de Pediatría Prof. Dr Juan P. Garrahan, Buenos…. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV-1, HIV Infections, Deoxyadenosines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: Fulbright-CONICET Scholar Award to P.C.A., Basic Science Core of the Texas D-CFAR.
Abstract (Originalsprache)
Background
Islatravir is a new antiretroviral drug that inhibits the reverse transcriptase (RT) of HIV-1 through multiple mechanisms. It is proposed to be used in combination with doravirine, a new NNRTI. M184V/I mutations have been shown to reduce the in vitro antiviral activity of islatravir, but their effect when pre-selected during ART has not been investigated.
Methods
HIV-1 rt sequences were obtained from four individuals of the Garrahan HIV cohort prior to, or during virological failure to ART. HIV-1 infectious molecular clones were constructed on an NL4-3 backbone, and infectious viruses were produced by transfection of 293T cells. Fold-changes in IC50 were calculated for each mutant versus the NL4-3 WT. HIV-1 phenotypic drug resistance was tested in vitro against NRTIs and NNRTIs.
Results
In all the cases, M184I/V, either alone or in the presence of other mutations, was associated with reduced susceptibility to islatravir, abacavir and lamivudine. Viruses carrying M184V/I showed variable levels of resistance to islatravir (4.8 to 33.8-fold). The greatest reduction in susceptibility was observed for viruses carrying the mutations M184V + V106I (33.8-fold resistance) or M184V + I142V (25.2-fold resistance). For NNRTIs, the presence of V106I alone did not affect susceptibility to doravirine or etravirine, but showed a modest reduction in susceptibility to efavirenz (6-fold). Susceptibility to doravirine was slightly reduced only for one of the mutants carrying V106I in combination with Y181C and M184V.
Conclusions
Mutations and polymorphisms selected in vivo together with M184V/I depend on the viral genetic context and on ART history, and could affect the efficacy of islatravir once available for use in the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Cellular Biology and Retroviruses, Unit of Virology and Molecular Epidemiology, Hospital de Pediatría Prof. Dr Juan P. Garrahan, Buenos Aires, Argentina.
- CONICET, Buenos Aires, Argentina.
- Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, USA.
- Unit of Epidemiology and Infectology, Hospital de Pediatría Prof. Dr Juan P. Garrahan, Buenos Aires, Argentina.
ORCID-Profile: Paula C Aulicino, Jason T Kimata
Förderung
- Fulbright-CONICET Scholar Award to P.C.A.
- Basic Science Core of the Texas D-CFAR
Zitieren
APA
Aulicino, P. C., Sharma, S., Truong, K., Kukunoor, V., Ghei, K., Arazi-Caillaud, S., Taicz, M., Bologna, R., Mangano, A., & Kimata, J. T. (2024). Variable antiviral activity of islatravir against M184I/V mutant HIV-1 selected during antiretroviral therapy. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad390
Vancouver
Aulicino PC, Sharma S, Truong K, Kukunoor V, Ghei K, Arazi-Caillaud S, et al. Variable antiviral activity of islatravir against M184I/V mutant HIV-1 selected during antiretroviral therapy. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkad390
BibTeX
@article{Aulicino2024,
author = {Aulicino, Paula C and Sharma, Suman and Truong, Khanghy and Kukunoor, Vindhya and Ghei, Karm and Arazi-Caillaud, Solange and Taicz, Moira and Bologna, Rosa and Mangano, Andrea and Kimata, Jason T},
title = {Variable antiviral activity of islatravir against M184I/V mutant HIV-1 selected during antiretroviral therapy},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkad390}
}
EUVIMED